At ASCO, the CHRYSALIS-2 study read-out showed that patients on the combination had overall survival of nearly three-and-a-half years.
In combination with Keytruda, the antibody-drug conjugate slowed progression compared to anti-PD-1 therapy alone.
The trial missed its primary endpoint but showed the test can detect cancers earlier, fueling questions around the best framework to evaluate MCED tests.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results